Abstract library

40 results for "Pande".
#903 Health-Related Quality-of-Life (HRQoL) in Patients (pts) with Advanced Neuroendocrine Tumors (NET) Treated with Everolimus (EVE): Results from an Open-label, Phase IIIb, Multicenter, Expanded Access Program (EAP)
Introduction: NET is associated with a considerable HRQoL burden.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Marianne Pavel
Authors: Pavel M, Unger N, Borbath I, Ricci S, ...
Keywords: everolimus, QoL, NET
#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study
Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Maria Pilar Solis-Hernandez
Keywords: sunitinib, PNET, choi, recist
#545 A Case of ACTH-Secreting Bronchial Carcinoid
Introduction: Ectopic ACTH syndrome (EAS) occurs in about 5-10% of ACTH-dependent hypercortisolism and, in up to 15% of cases, is related to occult neoplasms.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#601 Chromogranin A is a Sensitive Marker of Progression or Regression
Introduction: One of the most common is gastroenteropancreatic (GEP) NET of the pancreas, which constitute about 30% of all GEP NET. CgA is an excellent marker for NET and tumor volume and plasma CgA is suggested as the most reliable marker in follow-up of GEP but only few studies have been published.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Kenneth Jensen
#696 Downgrading Due to Ki-67 Index Assessment with Image Analysis
Introduction: The latest WHO classification for neuroendocrine tumors (NET) defines their grade according to Ki-67 and mitotic index. These parameters have both shown to be prognostic.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Marie-Louise Van Velthuysen
#797 Ganglioneuroma of Retroperitoean
Introduction: Ganglioneuromas presented as a retroperitoneal tumor around vital organs is a rare entity. A case with unusual presentation is reported. Forty-four-year-old woman presented without any complaint, found during incidental abdominopelvic ultrasound.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: medical oncology Mehrdad Payandeh
Authors: payandeh M, aeinfar M, ...
#943 SSA Therapy for Patients with Bronchial Carcinoids (BC) in the Community Setting
Introduction: SSA show antitumoral effect in GEP-NETs in 2 phase III trials, PROMID and CLARINET. However, patients (pts) with BC were not included in these studies.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Carlos Lopez Lopez
Keywords: bronchial, carcinoid, SSA
#1078 Somatostatin Responsive ACTH and Precursor Excess in a Midgut Mesentery NET
Introduction: ACTH production from a midgut mesentery NET is extremely rare (1). A 62y old woman presented with hypokalaemia (2mmol/L) and hyperpigmentation, 11y after surgery of a pT3N1Mx non-functional G1 NET with SRS positive, non-resectable but stable, residual mass encasing mesenteric vessels. Serum cortisol (3261 nmol/L), ACTH (796 ng/L), CgA (530 pmol/L) and urine total cortisol metabolites (33920 µg/24h) including 14 sub-products indicated change of biological behaviour into a functioning NET. Pituitary or pulmonary sources were excluded
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr., Ass Prof. Martin O. Weickert
#1141 New Hybrid SPECT-CT Modality for Imaging Purposes in Patients with Medullary Thyroid Cancer (MTC)
Introduction: Loco-regional lymph node and distant metastases are found very often in patients with MTC of less than 1 cm. There is not good MTC response to systemic chemotherapy or to external been radiotherapy. Radical thyroidectomy is the main method of therapy. Early diagnosis and correct N/M-staging are extremely important for the management of MTC. New hybrid SPECT-CT γ-cameras allow the fusion of anatomical and functional modalities. SPECT-CT is used in order to optimize somatostatin-receptor scintigraphic protocols.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Professor Sonya Sergieva
#1153 Prognostic Role of Diabetes Mellitus (DM) and Metformin (MET) Therapy in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs) Treated with Everolimus (EVE)
Introduction: MET has shown antitumorigenic effects on DM cancer pts, which are mediated by decrease of insulin/IGF-1 levels and activation of the AMPK pathway leading to mTOR inactivation.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Ana Custodio